Date  |
|
| Oct 1, 2018 |
Innovate Biopharmaceuticals Announces Participation at the Ladenburg Thalmann 2018 Healthcare Conference |
| Oct 29, 2018 |
Innovate Biopharmaceuticals Announces Positive Effect of Larazotide Acetate on reducing Intestinal Permeability in a NASH Preclinical Study |
| Oct 31, 2018 |
Innovate Biopharmaceuticals Announces Participation at the Jefferies 2018 London Healthcare Conference |
| Nov 5, 2018 |
Innovate Biopharmaceuticals Announces Presentation at the BIO-Europe Conference, Copenhagen 2018 - 24th Annual Partnering Conference |
| Nov 12, 2018 |
Sanyal Biotechnology and Innovate Biopharmaceuticals Present Data at AASLD Validating a Proprietary “Leaky Gut” Assay Demonstrating Reduced Intestinal Permeability with Larazotide Acetate Treatment in a NASH Preclinical Study |
| Nov 13, 2018 |
Innovate Biopharmaceuticals Reports Third Quarter 2018 Earnings and Key Corporate Highlights |
| Nov 26, 2018 |
Innovate Biopharmaceuticals Strengthens Clinical Development with the Addition of Patrick H. Griffin, M.D., F.A.C.P. |
| Dec 4, 2018 |
Innovate Biopharmaceuticals Enters into a Collaboration with Massachusetts General Hospital and Announces Capital Update for the Celiac Disease Clinical Program and its NASH Development Strategy on December 17, 2018 |
| Dec 17, 2018 |
Innovate Biopharmaceuticals Plans to Commence the First Ever Phase 3 Registration Trial in Celiac Disease in 1H 2019 and Announce Top-line NASH Data with Drug Combinations by EASL 2019 |